[
    [
        {
            "time": "2018-03-15",
            "original_text": "Top Stock Reports for Exxon Mobil, Eli Lilly & Costco",
            "features": {
                "keywords": [
                    "Exxon Mobil",
                    "Eli Lilly",
                    "Costco"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "healthcare",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Stock Reports for Exxon Mobil, Eli Lilly & Costco",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "2 Compelling Reasons to Buy This Reawakened Pharma Giant",
            "features": {
                "keywords": [
                    "Compelling Reasons",
                    "Pharma Giant"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2 Compelling Reasons to Buy This Reawakened Pharma Giant",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA",
            "features": {
                "keywords": [
                    "Lilly",
                    "Incyte",
                    "Olumiant",
                    "sNDA",
                    "FDA",
                    "Delayed"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]